3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
8
Glioblastoma
3
Squamous Cell Carcinoma of Head and Neck
2
Melanoma
2
Brain Neoplasms
2
Urothelial Carcinoma of the Bladder
1
Sarcoma
1
Oligodendroglioma
1
Non-Muscle Invasive Bladder Urothelial Carcinoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Nasopharyngeal Carcinoma
1
Muscle-invasive Urothelial Cancer of the Bladder
1
Mouth Neoplasms
1
Lymphoma, Follicular
1
Laryngeal Neoplasms
1
Glioma
1
Giant Cell Tumor of Bone
1
Ganglioneuroblastoma
1
Estrogen Receptor Positive Breast Cancer
1
Craniopharyngioma
1
Carcinoma
1
Astrocytoma
1
Alzheimer Disease
1
Interventions
pembrolizumab
90
Blood Specimen Collection
41
Cyclophosphamide
37
Bevacizumab
36
Nivolumab
35
Standard of Care
32
Carboplatin
31
Surveys and Questionnaires
29
Paclitaxel
27
atezolizumab
25
Exercise
25
Pemetrexed
24
Gemcitabine
23
Cisplatin
23
Fluorouracil
22
Radiotherapy
20
Leucovorin
20
Dexamethasone
20
Docetaxel
19
Oxaliplatin
18
Rituximab
16
Irinotecan
16
Cetuximab
16
dostarlimab
15
Drug Therapy
15
Doxorubicin
15
Ipilimumab
14
Biopsy
14
130-nm albumin-bound paclitaxel
14
fludarabine
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Transurethral Resection of Bladder
×
1 year
×
Clear all
NCT07067749
2025-07-24
TEMPO-MIBC
University of Rome Tor Vergata
Phase 3
Recruiting
92 enrolled